24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
Alan Thomas is a patient advocate for rare diseases, and ataxia in particular. He is known as the ‘rare disease warrior’ and, as a patient with a life-limiting rare disease, he can convey the patient engagement message from his point of view on all issues regarding the wellbeing of patients.
After finishing my undergraduate degree in biomedical sciences, I was eager to harness the skills I had developed and transfer them to a new environment. This led me to apply for an internship at Oxford PharmaGenesis.
Throughout the COVID-19 pandemic, Oxford PharmaGenesis has been in the fortunate position of being able to continue to recruit HealthScience experts for a variety of roles across our global locations. We asked a few of our new colleagues to share their experiences of joining us remotely.
Throughout the COVID-19 pandemic, our colleagues have volunteered their time in many different and inspiring ways. Read more about the experiences of two of our colleagues.
This year saw the first virtual edition of the Communiqué Awards, with Oxford PharmaGenesis strongly represented among a multitude of faces online, celebrating excellence in international healthcare communications. While the COVID-19 pandemic precluded the razzmatazz of the usual black-tie dinner and awards ceremony in London, the virtual event nevertheless continued the Communiqué mission to recognize…
Our perspective Champion sponsor of the Annual Meeting Written by Chris Winchester, CEO, Oxford PharmaGenesis This year’s virtual Annual Meeting of ISMPP marked the end of my 3 years on the Board of Trustees, and a chance to reflect on our achievements in that time. As well as managing the transition from one extremely talented President…
